中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2010年
9期
924-926
,共3页
慢性心力衰竭%促红细胞生成素%心功能%贫血
慢性心力衰竭%促紅細胞生成素%心功能%貧血
만성심력쇠갈%촉홍세포생성소%심공능%빈혈
Chronic heart failure%Erythropoietin%Heart function%Anemia
目的 探讨纠正贫血对改善慢性心力衰竭(CHF)合并贫血患者心功能的作用.方法 选择CHF合并贫血患者66例,随机分为2组,常规治疗组30例给予洋地黄制剂、利尿剂、血管扩张剂、血管紧张素转换酶抑制剂(ACEI)或β受体阻滞剂等常规药物治疗;观察组36例在常规药物治疗基础上加用促红细胞生成素(EPO)、铁剂、输红细胞等治疗.观察2组用药前与治疗3个月后心功能的变化.结果 观察组心功能改善的临床显效率[63.9%(23/36)]和总有效率[91.7%(33/36)]均较常规治疗组[33.3%(10/30)和56.7%(17/30)]显著提高(χ2值分别为6.73、10.91,P均＜0.01),且无明显的不良反应出现.治疗3个月后观察组与常规治疗组比较血红蛋白(Hb)浓度[(125.0±4.0)、(80.0±7.0)g/L]显著升高,左心室射血分数[(49.6±8.0)%、(34.7±10.0)%]、左心室舒张末内径[(4.9±0.7)、(6.0±0.4)cm]、左心室舒张末期容积[(130.1±24.0)、(148.3±30.8)ml]、左心室收缩末期容积[(72.5±32.0)、(79.7±25.0)ml]均有显著改善(P均＜0.01).结论 纠正贫血改善CHF合并贫血患者的心功能是一种比较安全有效的方法,能显著升高Hb浓度,改善心功能.
目的 探討糾正貧血對改善慢性心力衰竭(CHF)閤併貧血患者心功能的作用.方法 選擇CHF閤併貧血患者66例,隨機分為2組,常規治療組30例給予洋地黃製劑、利尿劑、血管擴張劑、血管緊張素轉換酶抑製劑(ACEI)或β受體阻滯劑等常規藥物治療;觀察組36例在常規藥物治療基礎上加用促紅細胞生成素(EPO)、鐵劑、輸紅細胞等治療.觀察2組用藥前與治療3箇月後心功能的變化.結果 觀察組心功能改善的臨床顯效率[63.9%(23/36)]和總有效率[91.7%(33/36)]均較常規治療組[33.3%(10/30)和56.7%(17/30)]顯著提高(χ2值分彆為6.73、10.91,P均＜0.01),且無明顯的不良反應齣現.治療3箇月後觀察組與常規治療組比較血紅蛋白(Hb)濃度[(125.0±4.0)、(80.0±7.0)g/L]顯著升高,左心室射血分數[(49.6±8.0)%、(34.7±10.0)%]、左心室舒張末內徑[(4.9±0.7)、(6.0±0.4)cm]、左心室舒張末期容積[(130.1±24.0)、(148.3±30.8)ml]、左心室收縮末期容積[(72.5±32.0)、(79.7±25.0)ml]均有顯著改善(P均＜0.01).結論 糾正貧血改善CHF閤併貧血患者的心功能是一種比較安全有效的方法,能顯著升高Hb濃度,改善心功能.
목적 탐토규정빈혈대개선만성심력쇠갈(CHF)합병빈혈환자심공능적작용.방법 선택CHF합병빈혈환자66례,수궤분위2조,상규치료조30례급여양지황제제、이뇨제、혈관확장제、혈관긴장소전환매억제제(ACEI)혹β수체조체제등상규약물치료;관찰조36례재상규약물치료기출상가용촉홍세포생성소(EPO)、철제、수홍세포등치료.관찰2조용약전여치료3개월후심공능적변화.결과 관찰조심공능개선적림상현효솔[63.9%(23/36)]화총유효솔[91.7%(33/36)]균교상규치료조[33.3%(10/30)화56.7%(17/30)]현저제고(χ2치분별위6.73、10.91,P균＜0.01),차무명현적불량반응출현.치료3개월후관찰조여상규치료조비교혈홍단백(Hb)농도[(125.0±4.0)、(80.0±7.0)g/L]현저승고,좌심실사혈분수[(49.6±8.0)%、(34.7±10.0)%]、좌심실서장말내경[(4.9±0.7)、(6.0±0.4)cm]、좌심실서장말기용적[(130.1±24.0)、(148.3±30.8)ml]、좌심실수축말기용적[(72.5±32.0)、(79.7±25.0)ml]균유현저개선(P균＜0.01).결론 규정빈혈개선CHF합병빈혈환자적심공능시일충비교안전유효적방법,능현저승고Hb농도,개선심공능.
Objective To investigate the role of correcting anemia in improving the heart function of chronic heart failure(CHF) with anemia. Methods Sixty-six CHF patients with anemia were randomly assigned to two groups. Thirty cases in the control group received routine treatment including digitalis, diuretics, vasodilator,ACEI or β-blocker,and 36 cases in the observe group received the above routine treatment and EPO,chalybeate and transferring hematid. Results Clinical efficiency ratio and total efficiency ratio were higher in the observe group (63. 9% ,91.7%) than in the control group(33.3% ,56. 7%) (χ2 =6. 73 and 10.91 ,P ＜0.01). After treatment for 3 months,Hb concentration, LVEF, LVDD, LEDV and LESV in the observe group were (125.0 ± 4. 0) g/L,(49.6±8.0)%,(4.9 ±0.7) cm,(130.1 ±24.0) ml and (72.5 ±32.0) ml respectively,which were all significantly improved than those in the control group [(80.0 ± 7.0) g/L, (34. 7 ± 10.0) %, (6. 0 ± 0.4) cm,(148. 3 ± 30.8) ml and (79. 7 ± 25. 0) ml] (P ＜ 0.01). Conclusions Correcting anemia is a safe and effective method in improveing the heart functionin CHF patients with anemia.
